

EPIX MEDICAL INC  
Form 8-K  
January 14, 2004

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

---

Date of Report (Date of earliest event reported): **January 13, 2004**

## EPIX Medical, Inc.

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other  
jurisdiction of  
incorporation)

**000-21863**  
(Commission  
File Number)

**04-3030815**  
(IRS Employer  
Identification No.)

**71 Rogers Street**  
**Cambridge, Massachusetts 02142**

(Address of principal executive offices) (Zip Code)

Edgar Filing: EPIX MEDICAL INC - Form 8-K

Registrant's telephone number, including area code: **(617) 250-6000**

---

**Item 5. Other Events.**

On January 13, 2004, Epix Medical, Inc. issued a press release announcing the issuance of U.S. Patent No. 6,676,929 granting composition-of-matter claims for the chemical structure of the Company's lead compound, MS-325 (gadofosveset), a contrast agent designed specifically for vascular imaging with magnetic resonance angiography (MRA). A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

**Item 7. Financial Statements and Exhibits.**

(c) The following exhibits are furnished with this report:

Exhibit Number	Description
99.1	Press Release dated January 13, 2004.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EPIX Medical, Inc.  
(Registrant)

Date: January 14, 2003

/s/ Peyton J. Marshall  
Peyton J. Marshall  
*Senior Vice-President,  
Finance and Administration,  
Chief Financial Officer*